ArticleThe neuroradiology journal2026
Ticagrelor use in ruptured aneurysms: A retrospective cohort study.
Article in The neuroradiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThe acute management of ruptured intracranial aneurysms sometimes requires stent placement, which necessitates the prompt initiation of an antiplatelet (APT) regimen, including Ticagrelor at our center.ObjectiveThis study aimed to assess patients with ruptured intracranial aneurysms who received Ticagrelor prior to or during aneurysm embolization. We evaluated procedural safety and clinical and imaging outcomes at 6 months follow-up.Patients and MethodsWe analyzed patients with aneurysmal subarachnoid hemorrhage treated with endovascular therapy (EVT) under a dual antiplatelet therapy (DAPT) regimen between January 2015 and January 2023, excluding those managed with surgical clipping. Safety profiles and clinical outcomes were systematically assessed.ResultsA total of 23 patients (69.6% female, mean age 58.6 ± 12.2 years) with ruptured aneurysms and subarachnoid hemorrhage underwent EVT with DAPT (Ticagrelor + Aspirin). Aneurysms were primarily located on the carotid (39.1%) and anterior communicating arteries (30.4%), with a median size of 5 mm. The median time from rupture to treatment was 1.5 days. Ischemic complications occurred in 30.4%, including procedure-related ischemia (21.7%) and post-procedure vasospasm (8.7%). Hemorrhagic complications were observed in 8.7%, with two patients experiencing asymptomatic post-procedure hemorrhage. Functional outcomes at 6 months showed 56.5% of patients with excellent recovery (mRS <2), while 17.4% died (mRS = 6), resulting in a 17.4% mortality rate.ConclusionTicagrelor appears feasible and generally safe for acute-phase management of aneurysmal subarachnoid hemorrhage, though complications and mortality highlight the need for cautious patient selection and further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.